Medtronic manufactures and sells device-based medical therapies. Its products include pacemakers, insertable cardiac monitors, implantable defibrillators, leads and delivery systems, ablation products, electrophysiology catheters, coronary and peripheral stents and related delivery systems, therapies for uncontrolled hypertension, endovascular stent graft systems, heart valve replacement technologies, and cardiac tissue ablation systems. The Company also manufactures image-guided surgery and intra-operative imaging systems.

Employee Rating

3.7More
TypePublic
HQMinneapolis, US
Founded1949
Size (employees)86,000 (est)
Websitemedtronic.com
Medtronic was founded in 1949 and is headquartered in Minneapolis, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Medtronic

Omar Ishrak

Omar Ishrak

CEO, Chairman
Karen Parkhill

Karen Parkhill

EVP, CFO
Richard Kuntz

Richard Kuntz

SVP, Chief Medical and Scientific Officer
Carol Surface

Carol Surface

SVP and Chief Human Resources Officer
Show more

Medtronic Office Locations

Medtronic has offices in Astana, Singapore, Dubai, Century City Cape Town and in 83 other locations
Minneapolis, US (HQ)
710 Medtronic Parkway
Doral, US
450 9850 NW 41st St
Doral, US
9850 NW 41st Street, Suite 450
Miami, US
Doral Corporate Centre II, 3750 NW 87th Avenue, Suite 700
Plymouth, US
3800 Annapolis Ln N #175
Portsmouth, US
180 International Dr
Show all (95)
Report incorrect company information

Medtronic Financials and Metrics

Medtronic Revenue

Embed Graph
Medtronic's revenue was reported to be $29.95 b in FY, 2018 which is a 0.8% increase from the previous period.
USD

Revenue (Q1, 2019)

7.4b

Gross profit (Q1, 2019)

5.2b

Gross profit margin (Q1, 2019), %

70.2%

Net income (Q1, 2019)

1.1b

EBIT (Q1, 2019)

1.2b

Market capitalization (9-Nov-2018)

127.7b

Closing stock price (9-Nov-2018)

94.4

Cash (27-Jul-2018)

4.4b

EV

147.0b
Medtronic's current market capitalization is $127.7 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

17.0b20.3b28.8b29.7b30.0b

Revenue growth, %

19%42%3%1%

Cost of goods sold

4.3b6.3b9.1b9.3b9.1b

Gross profit

12.7b14.0b19.7b20.4b20.9b
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

7.3b7.1b6.9b7.2b7.3b7.3b7.4b7.1b21.8b7.4b

Cost of goods sold

2.5b2.2b2.1b2.3b2.3b2.3b2.3b2.1b6.7b2.2b

Gross profit

4.8b4.9b4.8b4.9b5.0b5.0b5.0b4.9b15.1b5.2b

Gross profit Margin, %

66%69%69%68%68%69%68%70%69%70%
Annual
USDY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

13.2m4.8b186.4m5.0b3.7b

Accounts Receivable

17.1m5.6b6.0b

Inventories

1.7b3.5b3.5b3.3b3.6b

Current Assets

21.2b30.8b23.6b24.9b23.0b
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

46.0k3.0b2.4b2.7b3.1b3.0b2.8b4.7b5.5b6.4b4.4b

Accounts Receivable

(68.0m)

Inventories

3.4b3.5b3.5b3.6b3.7b3.7b3.5b3.8b3.7b

Current Assets

46.0k29.1b28.7b27.6b23.5b22.5b22.4b24.8b25.2b26.6b22.5b
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

3.1b2.7b3.5b4.0b3.1b

Depreciation and Amortization

349.0m1.3b2.8b2.0b2.6b

Inventories

(39.0m)(282.0m)(186.0m)(227.0m)(192.0m)

Accounts Payable

Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(37.1m)820.0m1.3b2.4b929.0m2.0b2.9b1.0b3.0b1.6b1.1b

Depreciation and Amortization

701.0m1.4b2.1b737.0m1.5b2.2b636.0m1.3b2.0b666.0m

Inventories

(207.0m)(326.0m)(388.0m)(101.0m)(187.0m)(261.0m)(273.0m)(318.0m)(180.0m)

Accounts Payable

1.3b1.4b1.4b(307.0m)13.0m85.0m
USDY, 2018

EV/EBIT

118.9 x

EV/CFO

86.4 x

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.8 x
Show all financial metrics

Medtronic Operating Metrics

Medtronic's Patients was reported to be 65 m in FY, 2016.
FY, 2014FY, 2015FY, 2016

Countries

160 160

Patents Issued

27 k53 k45 k

Patients

65 m
Show all operating metrics

Medtronic Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Mazor RoboticsSeptember 21, 2018$1.64 b
Visionsense LtdApril 11, 2018$75 m

Medtronic Revenue Breakdown

Embed Graph

Medtronic revenue breakdown by business segment: 7.1% from Diabetes Group, 25.9% from Restorative Therapies Group, 37.9% from Cardiac and Vascular Group and 29.1% from Minimally Invasive Therapies Group

Medtronic revenue breakdown by geographic segment: 46.7% from Rest of World, 53.0% from United States and 0.3% from Other

Human Capital Metrics

Medtronic's employees are reported to be approximately 49% female and 51% male.
Embed Graph
Show all human capital metrics
Report incorrect company information

Medtronic Online and Social Media Presence

Embed Graph
Report incorrect company information

Medtronic News and Updates

Cardiac Rhythm Management Market Size, Trends, Segments, Analysis with Key Player List: Medtronic Plc, St. Jude Medical Inc, Boston Scientific Corporation, Abbott Laboratories, Biotronik - 2025

Cardiac rhythm management market is the established segment of cardiology devices market, used majorly in the treatment of patients suffering from congestive heart failure (CHF) and atrial fibrillation (AF). Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Cranial Fixation and Stabilization Devices Market, 2018-2025 with Stryker, Medtronic, Ostomed, Johnson & Johnson, Integra LifeSciences, KLS Martin, and Braun Dominating

DUBLIN, Nov. 13, 2018 /PRNewswire/ -- The "Cranial Fixation and Stabilization Devices Market Size, Share & Trends Analysis Report By Product (Fixation Devices, Stabilization Devices), By End Use (Hospitals, ASCs), And Segment Forecasts, 2018 - 2025" report has been added to...

Liver Biopsy Market Will Touch a New Level in Upcoming Year – Key Players Involved in the Research Like Boston Scientific Corporation, INRAD Inc., Argon Medical Devices Inc., Medtronic

Liver Biopsy Market from Qurate’s Repository provides detailed information, in depth analysis and forecast which is developed by team of experts and professionals. Posted via Industry Today. Follow us on Twitter @IndustryToday

Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2019

DUBLIN - November 9, 2018 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com.…

Medtronic Delivers Significant Progress on Global Corporate Citizenship Efforts

2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals

Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication

FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension
Show more
Report incorrect company information

Medtronic Company Life and Culture

Report incorrect company information

Medtronic Frequently Asked Questions

wdxefcqufszuzezftuxetqsqxt
  • When was Medtronic founded?

    Medtronic was founded in 1949.

  • Who are Medtronic key executives?

    Medtronic's key executives are Omar Ishrak, Karen Parkhill and Richard Kuntz.

  • How many employees does Medtronic have?

    Medtronic has 86,000 employees.

  • What is Medtronic revenue?

    Latest Medtronic annual revenue is $30 b.

  • What is Medtronic revenue per employee?

    Latest Medtronic revenue per employee is $348.3 k.

  • Who are Medtronic competitors?

    Competitors of Medtronic include Olympus Corporation, Nikkiso and Boston Scientific.

  • Where is Medtronic headquarters?

    Medtronic headquarters is located at 710 Medtronic Parkway, Minneapolis.

  • Where are Medtronic offices?

    Medtronic has offices in Astana, Singapore, Dubai, Century City Cape Town and in 83 other locations.

  • How many offices does Medtronic have?

    Medtronic has 95 offices.